What is the share price of SeQuent Scientific Ltd (SEQUENT) today?
The share price of SEQUENT as on 16th September 2025 is ₹182.19. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on SeQuent Scientific Ltd (SEQUENT) share?
The past returns of SeQuent Scientific Ltd (SEQUENT) share are- Past 1 week: -2.14%
- Past 1 month: 3.65%
- Past 3 months: -8.03%
- Past 6 months: 38.36%
- Past 1 year: 1.91%
- Past 3 years: 59.63%
- Past 5 years: 18.42%
What are the peers or stocks similar to SeQuent Scientific Ltd (SEQUENT)?
The peers or stocks similar to SeQuent Scientific Ltd (SEQUENT) include:What is the market cap of SeQuent Scientific Ltd (SEQUENT) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SeQuent Scientific Ltd (SEQUENT) is ₹4558.00 Cr as of 16th September 2025.What is the 52 week high and low of SeQuent Scientific Ltd (SEQUENT) share?
The 52-week high of SeQuent Scientific Ltd (SEQUENT) is ₹240.70 and the 52-week low is ₹117.35.What is the PE and PB ratio of SeQuent Scientific Ltd (SEQUENT) stock?
The P/E (price-to-earnings) ratio of SeQuent Scientific Ltd (SEQUENT) is 208.41. The P/B (price-to-book) ratio is 5.92.Which sector does SeQuent Scientific Ltd (SEQUENT) belong to?
SeQuent Scientific Ltd (SEQUENT) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy SeQuent Scientific Ltd (SEQUENT) shares?
You can directly buy SeQuent Scientific Ltd (SEQUENT) shares on Tickertape. Simply sign up, connect your demat account and place your order.
SeQuent Scientific Ltd
SEQUENT Share Price
182.190.42% (+0.77)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SEQUENT Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SEQUENT Performance & Key Metrics
SEQUENT Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 153.57 | 5.92 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.23 | 5.88 | 0.58% |
SEQUENT Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SEQUENT Company Profile
SeQuent Scientific Limited is a holding company that operates in pharmaceutical sector.
SUNPHARMA
PE Ratio
35.17
35.17
1Y Return
14.01%
14.01%
Buy Reco %
86.11
86.11
CIPLA
PE Ratio
23.72
23.72
1Y Return
6.70%
6.70%
Buy Reco %
66.67
66.67
TORNTPHARM
PE Ratio
62.54
62.54
1Y Return
2.25%
2.25%
Buy Reco %
76.00
76.00
DRREDDY
PE Ratio
19.15
19.15
1Y Return
2.15%
2.15%
Buy Reco %
40.00
40.00
MANKIND
PE Ratio
53.60
53.60
1Y Return
5.26%
5.26%
Buy Reco %
81.25
81.25
SEQUENT Sentiment Analysis
SEQUENT Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SEQUENT Stock Summary · August 2025
In Q1 FY '26, the company demonstrated robust financial performance, achieving a 13.1% year-on-year revenue growth, driven by strategic initiatives and operational efficiencies. The ongoing merger with Viyash Life Sciences is anticipated to unlock significant synergies, enhancing both market positioning and financial health, while the focus on expanding into emerging markets has resulted in a notable 25% growth in exports. Despite challenges such as rising input costs and regulatory hurdles, management remains optimistic about sustaining double-digit growth, particularly in the high-margin generic animal health sector. Efforts to streamline operations and enhance product offerings, especially in the companion animal segment, are expected to further bolster profitability and gross margins in the coming quarters.
SEQUENT Stock Growth Drivers
SEQUENT Stock Growth Drivers
8Strong Financial Performance
SeQuent Scientific reported impressive financial results for Q1 FY '26, with total revenues reaching INR
Successful Market Expansion
The company has successfully expanded its presence in emerging markets, achieving a 25% year-on-year growth
SEQUENT Stock Challenges
SEQUENT Stock Challenges
2Sales Fluctuations Due to Seasonality
The company has experienced significant fluctuations in sales performance, particularly in the dairy cattle sector,
Concerns Over Future Sales Consistency
Despite the current fluctuations, there is an emphasis on the expectation of double-digit growth for
SEQUENT Forecast
SEQUENT Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SEQUENT
SEQUENT
Income
Balance Sheet
Cash Flow
Annual Normal View
SEQUENT Income Statement
SEQUENT Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 694.65 | 1,292.62 | 1,047.98 | 1,189.33 | 1,369.98 | 1,423.67 | 1,427.30 | 1,395.45 | 1,570.34 | 1,618.46 | ||||||||||
Raw Materials | 366.89 | 486.44 | 570.52 | 600.59 | 733.68 | 842.41 | 814.87 | 789.20 | 829.94 | 1,436.77 | ||||||||||
| Power & Fuel Cost | 12.77 | 14.66 | 23.06 | 24.73 | 28.75 | 33.86 | 42.45 | 35.46 | 32.98 | |||||||||||
| Employee Cost | 106.22 | 113.83 | 145.95 | 165.06 | 187.22 | 231.37 | 258.39 | 250.57 | 281.12 | |||||||||||
| Selling & Administrative Expenses | 74.68 | 94.72 | 90.93 | 108.27 | 115.85 | 132.65 | 139.02 | 138.35 | 159.09 | |||||||||||
| Operating & Other expenses | 82.59 | 64.28 | 83.92 | 110.27 | 92.86 | 63.12 | 219.02 | 126.88 | 95.71 | |||||||||||
EBITDA | 51.50 | 518.69 | 133.60 | 180.41 | 211.62 | 120.26 | -46.45 | 54.99 | 171.50 | 181.69 | ||||||||||
| Depreciation/Amortization | 40.07 | 41.34 | 41.92 | 50.62 | 50.60 | 51.54 | 55.69 | 61.54 | 66.45 | 65.33 | ||||||||||
| PBIT | 11.43 | 477.35 | 91.68 | 129.79 | 161.02 | 68.72 | -102.14 | -6.55 | 105.05 | 116.36 | ||||||||||
| Interest & Other Items | 28.34 | 33.07 | 32.80 | 35.71 | 24.38 | 15.77 | 35.52 | 48.09 | 60.75 | 58.53 | ||||||||||
| PBT | -16.91 | 444.28 | 58.88 | 94.08 | 136.64 | 52.95 | -137.66 | -54.64 | 44.30 | 57.83 | ||||||||||
| Taxes & Other Items | -3.08 | 22.72 | 10.22 | 24.17 | 41.19 | 11.98 | -16.50 | -18.77 | 22.43 | 28.15 | ||||||||||
| Net Income | -13.83 | 421.56 | 48.66 | 69.91 | 95.45 | 40.97 | -121.16 | -35.87 | 21.87 | 29.68 | ||||||||||
| EPS | -0.53 | 15.98 | 1.91 | 2.82 | 3.84 | 1.65 | -4.87 | -1.44 | 0.88 | 1.19 | ||||||||||
| DPS | 0.00 | 0.18 | 0.20 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.01 | 0.10 | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SEQUENT Company Updates
SEQUENT Stock Peers
SEQUENT Past Performance & Peer Comparison
SEQUENT Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| SeQuent Scientific Ltd | 208.41 | 5.92 | — |
| Sun Pharmaceutical Industries Ltd | 35.17 | 5.30 | 1.00% |
| Cipla Ltd | 23.72 | 4.00 | 1.03% |
| Torrent Pharmaceuticals Ltd | 62.54 | 15.75 | 0.91% |
SEQUENT Stock Price Comparison
Compare SEQUENT with any stock or ETFCompare SEQUENT with any stock or ETF
SEQUENT
SEQUENT Holdings
SEQUENT Shareholdings
SEQUENT Promoter Holdings Trend
SEQUENT Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SEQUENT Institutional Holdings Trend
SEQUENT Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SEQUENT Shareholding Pattern
SEQUENT Shareholding Pattern
SEQUENT Shareholding History
SEQUENT Shareholding History
Foreign Institutions
Mutual Funds Invested in SEQUENT
Mutual Funds Invested in SEQUENT
No mutual funds holding trends are available
Top 5 Mutual Funds holding SeQuent Scientific Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 8.3116% | Percentage of the fund’s portfolio invested in the stock 1.33% | Change in the portfolio weight of the stock over the last 3 months -0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/113 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5456% | Percentage of the fund’s portfolio invested in the stock 6.51% | Change in the portfolio weight of the stock over the last 3 months -0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/32 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3218% | Percentage of the fund’s portfolio invested in the stock 1.32% | Change in the portfolio weight of the stock over the last 3 months -0.21% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/43 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SEQUENT stock
smallcases containing SEQUENT stock
Looks like this stock is not in any smallcase yet.
SEQUENT Events
SEQUENT Events
SEQUENT Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SEQUENT Dividend Trend
No dividend trend available
SEQUENT Upcoming Dividends
SEQUENT Upcoming Dividends
No upcoming dividends are available
SEQUENT Past Dividends
SEQUENT Past Dividends
Cash Dividend
Ex DateEx DateSep 8, 2021
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateAug 21, 2019
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Aug 21, 2019
Cash Dividend
Ex DateEx DateNov 20, 2017
Interim
Interim | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Nov 20, 2017
Cash Dividend
Ex DateEx DateSep 16, 2011
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 16, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 23, 2010
SEQUENT Stock News & Opinions
SEQUENT Stock News & Opinions
Articles & Videos
Earnings
Sequent Scientific consolidated net profit rises 119.82% in the June 2025 quarter
Net profit of Sequent Scientific rose 119.82% to Rs 14.31 crore in the quarter ended June 2025 as against Rs 6.51 crore during the previous quarter ended June 2024. Sales rose 13.12% to Rs 441.42 crore in the quarter ended June 2025 as against Rs 390.21 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales441.42390.21 13 OPM %11.8210.75 - PBDT41.9028.25 48 PBT26.7712.00 123 NP14.316.51 120 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sequent Scientific to convene board meeting
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sequent Scientific to conduct EGM
Sequent Scientific announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 26 August 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sequent Scientific schedules EGM
Sequent Scientific announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 30 August 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sequent Scientific schedules AGM
Sequent Scientific announced that the 40th Annual General Meeting(AGM) of the company will be held on 8 August 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Sequent Scientific allots 30,000 equity shares under ESOP
Sequent Scientific has allotted 30,000 equity shares under ESOP on 26 June 2025. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs. 50,06,09,990 consisting of 25,03,04,995 equity shares of Rs. 2 each to Rs.50,06,69,990 consisting of 25,03,34,995 equity shares of Rs. 2 each. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Sequent Scientific allots Equity shares
Sequent Scientific has approved the issue and allotment of 3,000 Equity Shares of Rs. 2/- each fully paid to one Employee at an exercise price of Rs. 86/- per equity share on exercise of the options granted to him under SeQuent ESOP 2020.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Sequent Scientific reports consolidated net profit of Rs 9.32 crore in the March 2025 quarter
Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales401.70361.20 11 1551.371369.73 13 OPM %11.518.93 -10.434.48 - PBDT32.7723.83 38 115.7324.28 377 PBT16.657.35 127 49.28-37.26 LP NP9.32-0.92 LP 21.88-35.88 LP Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Sequent Scientific to hold board meeting
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Sequent Scientific consolidated net profit declines 58.40% in the December 2024 quarter
Net profit of Sequent Scientific declined 58.40% to Rs 3.44 crore in the quarter ended December 2024 as against Rs 8.27 crore during the previous quarter ended December 2023. Sales rose 18.66% to Rs 390.81 crore in the quarter ended December 2024 as against Rs 329.36 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales390.81329.36 19 OPM %8.836.76 - PBDT25.3914.19 79 PBT8.41-1.27 LP NP3.448.27 -58 Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.72%, vs industry avg of 9.99%
Over the last 5 years, market share decreased from 0.47% to 0.38%
Over the last 5 years, net income has grown at a yearly rate of -20.74%, vs industry avg of 20.01%